- Report
- February 2024
- 130 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- January 2024
- 120 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- November 2023
- 200 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- September 2022
- 62 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- June 2021
- 77 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- November 2021
- 73 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- July 2021
- 35 Pages
Global
- Report
- June 2021
Global
From €2662EUR$2,800USD£2,236GBP
€3803EUR$4,000USD£3,195GBP
- Report
- February 2025
- 85 Pages
Saudi Arabia
From €3327EUR$3,500USD£2,795GBP
- Report
- January 2025
- 85 Pages
Saudi Arabia
From €3327EUR$3,500USD£2,795GBP
- Report
- October 2023
- 190 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2023
- 183 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- February 2025
- 85 Pages
India
From €3327EUR$3,500USD£2,795GBP
- Report
- October 2023
- 190 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2023
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- February 2024
- 114 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- February 2024
- 124 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- February 2024
- 120 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- February 2024
- 184 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Drug Pipelines
- January 2024
- 70 Pages
Global
From €1901EUR$2,000USD£1,597GBP

RNA interference (RNAi) is a biotechnological process that uses small pieces of double-stranded RNA (dsRNA) to inhibit gene expression. It is a powerful tool for studying gene function and has been used to develop treatments for a variety of diseases. RNAi has been used to target and silence specific genes, allowing researchers to study the effects of gene silencing on cell function. It has also been used to develop treatments for cancer, viral infections, and other diseases.
RNAi technology has been used to develop a variety of therapeutics, including small interfering RNAs (siRNAs), microRNAs (miRNAs), and antisense oligonucleotides (ASOs). siRNAs are short pieces of dsRNA that can be used to target and silence specific genes. miRNAs are small pieces of single-stranded RNA that can regulate gene expression. ASOs are short pieces of DNA that can be used to target and silence specific genes.
The RNAi market is a rapidly growing segment of the biotechnology industry. Companies in the market include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, BioNTech, Editas Medicine, and Moderna Therapeutics. These companies are developing a variety of RNAi-based therapeutics for a range of diseases. Show Less Read more